KESTRA MEDICAL TECHNOLOGIES, LTD.

Kestra Medical Technologies, Inc.

Company snapshot

Kestra Medical Technologies is a commercial-stage wearable medical device and digital healthcare company focused on cardiovascular recovery. Its Cardiac Recovery System is anchored by the ASSURE Wearable Cardioverter Defibrillator (WCD), which monitors heart rhythms and delivers defibrillation when required, and is supported by digital health tools and services for patients during recovery.

Core platform and products

• ASSURE WCD
  • Primary device for rhythm monitoring and therapeutic shocks.
  • FDA PMA approved July 27, 2021; commercial launch August 2022.
• Cardiac Recovery System (integrated ecosystem)
  • ASSURE Patient App: real-time mobile connectivity for patient engagement.
  • Kestra CareStation: remote patient management platform with alert-based notifications and patient data.
  • Heart Alert Services: detection of significant arrhythmias.
  • ASSURE Assist: emergency services notification when a therapeutic shock is delivered.
• Recent enhancements and collaborations
  • Enhanced ASSURE Detection Algorithm (ACE-PAS data incorporated) announced April 2026 to reduce false alarms.
  • Collaboration with Biobeat (January 2026) to integrate cuffless ABPM data for hypertension management into the ASSURE WCD portfolio.

Market size and opportunity

• U.S. total addressable market (TAM) for WCDs: approximately $10 billion annually.
• International TAM outside the U.S.: approximately $14 billion annually.
• International expansion plans: pursuing CE Mark in Europe, with Western Europe as the initial focus and an aim to begin distribution in select Western European markets within roughly three years.

Performance and scale

• Employees: over 443 full-time team members (as of April 30, 2026).
• Sales force and support
  • Direct sales representatives: approximately 130.
  • Sales and clinical support: more than 40.
  • ASSURE Patient Specialists (APS): over 500 for patient fitting and training (as of April 30, 2026; up from 300 in April 2025).
• Patient reach and clinical program
  • ASSURE WCD has protected nearly 40,000 patients since commercial launch (as of April 30, 2026).
  • ACE-PAS (post-approval study) enrolled 21,612 patients across the U.S.; primary results announced November 2025.
  • ACE-PAS outcomes: median wear time >23 hours/day; 100% VT/VF conversion rate; 0.0065 inappropriate shocks per patient-month; 6% false alarms.

Revenue model and financial position

• Revenue model: primarily from leasing the ASSURE WCD to patients as part of the Cardiac Recovery System; patient wear time drives payor reimbursement.
• Fiscal year ended April 30, 2026: net loss of $131.6 million.
• Fiscal year ended April 30, 2025: net loss of $113.8 million.
• Accumulated deficit: $651.9 million (as of April 30, 2026).
• Debt and liquidity
  • Outstanding debt under the 2024 Term Loan was $45.0 million (as of April 30, 2026).
  • On July 10, 2026, Kestra entered a new Term Loan that paid off and terminated the 2024 Term Loan.
  • The new Term Loan requires quarterly interest payments and imposes covenants; it is collateralized by substantially all assets and includes liquidity and other non-financial covenants.

Intellectual property and regulatory landscape

• Intellectual property: 264 issued U.S. and foreign patents and 125 pending patent applications (as of April 30, 2026). Earliest issued patent expiries around February 2031.
• Trademarks: ASSURE, CARDIAC RECOVERY SYSTEM, KESTRA, KESTRA CARESTATION, ASSURE ASSIST.
• Regulation: ASSURE WCD is a Class III device subject to FDA PMA; broader digital health components are Class I (510(k) exempt). The company addresses CMS/Medicare reimbursement and DMEPOS requirements and complies with privacy and data security obligations (HIPAA/HITECH and GDPR considerations for international operations).

Manufacturing, supply chain, and operations

• Manufacturing model: outsourced to tier-one contract manufacturers. Devices are leased and refurbished for reuse; reconditioning and lifecycle management are validated and FDA-approved.
• Inventory and distribution: central distribution location plus about 20 third-party warehouses across the U.S.; components are typically replenished within 24 hours.
• International readiness: tier-one partners have facilities in Asia and Europe to support potential international expansion; supply chain risks include single-source components and the need for contingency planning.
• Partnerships and ecosystem: collaboration with Biobeat for ABPM data and plans to integrate additional monitoring and digital capabilities to extend the platform beyond WCD wear.

Strategic and risk context

• Competitive position: the WCD market has been dominated by LifeVest (ZOLL); new entrants, including an adhesive-based external defibrillator FDA-approved in 2025, increase competition.
• Growth strategy: expand U.S. share of WCD prescriptions, broaden Cardiac Recovery System adoption, grow international presence, strengthen payor engagement, deepen clinical evidence, and explore adjacent markets with new products and services.
• Public company considerations: ongoing costs and governance obligations associated with being a public company, and exposure to macroeconomic conditions that can affect financing and demand.

Summary

Kestra Medical Technologies commercializes the Cardiac Recovery System centered on the ASSURE WCD, combining a wearable defibrillator with an integrated digital health platform to support recovery from high-risk cardiac events. The company has a growing U.S. footprint and international plans, a sizable patient population protected to date, an expanding direct sales and APS workforce, ongoing clinical evidence generation, and a strategic focus on scaling revenues and achieving profitability while managing debt and operational risks.